Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 104

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 104
---
 The NLS Board has determined that the Merger and the other Proposals to be presented at the NLS Meeting are fair to and in the best interest of NLS’s shareholders and unanimously recommends that its shareholders vote •“FOR” Proposal No. 1 to approve the Merger Agreement. •“FOR” Proposal No. 2 to approve the par value reduction, reverse split and ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •“FOR” Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of NLS Preferred Shares. •“FOR” Proposal No. 4 to approve the reinstatement of the capital band. •“FOR” Proposal No. 5 to approve the conditional share capital for employee and advisory options. •“FOR” Proposal No. 6 to approve the conditional share capital for shareholders’ options. •“FOR” Proposal No. 7 to approve the transfer and voting rights limitation of 9.99%. •“FOR” Proposal No. 8 to approve the name change of NLS. •“FOR” Proposal No. 9 to approve the election of the new members to the NLS Board. •“FOR” Proposal No. 10 to approve the election of members of the Compensation, Nomination and Governance Committee. •“FOR” Proposal No. 11 to approve the composition of the new senior management following the Merger. •“FOR” Proposal No. 12.1 to approve the compensation for the members of the NLS Board. 7 •“FOR” Proposal No. 12.2 to approve the compensation for the executive officers. •“FOR” Proposal No. 13 to approve the CVR Agreement. •“FOR” Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Reasons for the Merger (Page 133) In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, the NLS Board took into account information presented during the process and considered the following factors that it viewed as supporting its decision to approve the Merger Agreement: Strategic Considerations •Advantages •Complementary Strengths: The Merger enables the combined company to integrate its diverse expertise, technologies, and product pipelines, leading to more holistic solutions in its target market. Specifically: •Technology & R&D Synergies: NLS and Kadimastem bring together distinct but complementary research capabilities, accelerating innovation